Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Globenewswire·2025-06-20 23:34
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes Association (ADA) Scientific Sessions.1,2Oral amycretin phase 1 data on the safety, tolerability and weight loss potential in people with overweight or obesity was also published in The Lancet.3Findings from the clinical trials indicate amycretin appeared tolerable with a safety profile consistent with other GLP- ...